



## 30<sup>th</sup> Annual Cancer Progress Conference May 7-8, 2019 Convене, 32 Old Slip, NYC

### May 7, 2019

7:00 – 8:00am

**Registration and Continental Breakfast**

8:00 – 8:15am

**Opening Remarks**

Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Cello Health BioConsulting, previously Defined Health

8:15 – 9:15am

**Keynote:**

***Realizing the Full Potential of CRISPR for Cancer Therapies and Other Precision Medicines***

**Speaker:** Rachel Haurwitz, PhD, Chief Executive Officer and Founder, Caribou Biosciences, Inc.

9:15 – 10:30am

**Has the Time Come for Chemo- & Immuno-Prevention: Nixing the Nabobs of Negativity**

**Moderator:** Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Cello Health BioConsulting, previously Defined Health

**Panelists:**

- John Letterio, MD, Division Chief, Pediatric Hematology and Oncology, UH Cleveland Medical Center Division Chief, Pediatric Hematology and Oncology, UH Rainbow Babies and Children's Hospital Professor, Pediatrics, CWRU School of Medicine Interim Director, UH Seidman Cancer Center
- Nicholas Sarlis, MD, PhD, FACP, FAPCR, Chief Medical Officer & Executive VP, Sellas Life Sciences Group, Inc.
- Michael B. Sporn, MD, Professor of Pharmacology and Medicine/Molecular and Systems Biology/Active Emeritus, Dartmouth Medical School

10:30 – 11:00am

**Networking Break**

11:00 – 12:15pm

**Novel Ways to Target and Develop Therapies for Cancer Metastases: Stop Spreading the New**

**Moderator:** Joel S. Sandler, PhD, Associate Principal, Cello Health BioConsulting, previously Defined Health

**Panelists:**

- Yibin Kang, PhD, Warner-Lambert/Parke-Davis Professor of Molecular Biology, Princeton University
- Llew Kerner, MD, PhD, CEO, Epistat
- Chand Khanna, DVM, PhD, DACVP, Director, Vuja De Sciences Chief Science Officer, Ethos Veterinary Health, President, Ethos Discovery Vuja De
- Jackson Streeter MD, Senior VP Corporate Development and Strategy, Quanterix
- Maurice Zauderer, PhD, President & Chief Executive Officer, Vaccinex, Inc.



12:15 – 1:30pm

**Networking Luncheon & Keynote:**

***Forward Thinking on the Future Oncology Biotech Supply Channel and Realities for Value Based Contracting***

**Speaker:** Burt Zweigenhaft, Managing Partner, Upstream Partners Inc.

1:30 – 2:45pm

**Basket Trials Revisited: Faster, Better, Smarter Trials/Precision Medicine: Insights and Remaining Challenges, Perspectives from Academia, Pharma and Biotech**

**Moderator:** Brian Leyland Jones, MBBS, PhD, VP, Avera Cancer Institute Center for Precision Oncology & Dept. of Molecular & Experimental Medicine, Avera Cancer Institute

**Panelists:**

- Peter J. O'Dwyer, MD, Group Co-Chair, ECOG-ACRIN Cancer Research Group; Abramson Cancer Center, University of Pennsylvania
- Richard L. Schilsky, MD, FACP, FSCT, FASCO, Senior Vice President and Chief Medical Officer, American Society of Clinical Oncology
- Gisela Schwab, MD, President, Product Development and Medical Affairs and Chief Medical Officer, Exelixis, Inc.
- Apostolia-Maria Tsimberidou, MD, PhD, Professor, Department of Investigational Cancer Therapeutics M. D. Anderson Cancer Center, University of Texas

2:45 – 3:15pm

**Networking Break**

3:15 – 4:30pm

**IO Session I: Combination Failures & Futures: Much Ado About What?**

**Moderator:** Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Cello Health BioConsulting, previously Defined Health

**Panelists**

- Kapil Dhingra, MD, Managing Member, KAPital Consulting LLC
- Axel Hoos, MD, PhD, SVP Therapeutic Area Head R&D, Head Immuno-Oncology, GlaxoSmithKline
- Ramy Ibrahim, MD, Chief Medical Officer, Parker Institute For Cancer Immunotherapy
- Vanessa Lucey, PhD, MBA, Director, Cancer Research Institute
- Robert Stein, MD, PhD, Senior R&D Advisor, Agenus
- Mai-Britt Zocca, PhD, Chief Executive Officer, IO Biotech

5:00 – 7:00pm

**Cancer Progress 2019 Reception**



**May 8, 2019**

**7:00 – 8:00am**

**Registration and Continental Breakfast**

**8:00 – 8:15am**

**Opening Remarks: Review of Day 1**

Joel S. Sandler, PhD, Associate Principal, Cello Health BioConsulting, previously Defined Health

**8:15 – 9:30am**

**Payer/Access Panel**

**Moderator:** Ed Saltzman, Executive Chairman, Cello Health BioConsulting, previously Defined Health

**Panelists**

- Peter Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- Roger Longman, Chief Executive Officer, Real Endpoints
- Burt Zweigenhaft, Managing Partner, Upstream Partners Inc.

**9:30 – 10:45am**

**IO Session II: IO Targets and Platforms - Target Versus Modality - What Are the Keys to the Kingdom?**

**Moderator:** Joel S. Sandler, PhD, Associate Principal, Cello Health BioConsulting, previously Defined Health

**Panelists:**

- Frank Borriello, Founder & Chief Executive Officer, Alloplex Biotherapeutics
- Ramy Ibrahim, MD, Chief Medical Officer, Parker Institute For Cancer Immunotherapy
- Louis Matis, MD, SVP and Chief Development Officer, Pieris Pharmaceuticals
- Eric Poma, MD, PhD, CEO/CSO, Molecular Templates, Inc.
- Dan Shoemaker, PhD, CSO, Fate Therapeutics

**10:45 – 11:15am**

**Networking Break**

**11:15am – 12:30pm**

**Gynecological & Breast Cancers, Much Progress, Much to Do: How Novel Therapies from PARPs to Immunotherapies Are Transforming Care**

**Moderator:** James T. Lee, PhD, Associate Principal, Oncology Lead, Cello Health BioConsulting, previously Defined Health

**Panelists**

- Brian Leyland Jones, MBBS, PhD, VP, Avera Cancer Institute Center for Precision Onc & Dept of Molecular & Experimental Medicine, Avera Cancer Institute
- Martin Lehr, CEO, Context Therapeutics
- Patrick Mahaffy, President & CEO, Clovis Oncology
- Dmitry Zamarin, MD, PhD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center



12:30 – 1:45pm

**Biotech Deal-Making in the Face of IO Frenzy or Fatigue: Same Old or Different New?**

**Moderator:** Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Cello Health BioConsulting, previously Defined Health

**Panelists:**

- Jean Chang, Vice President, Corporate Development & Oncology Project Lead, Dynavax
- Jane Dancer, Chief Business Officer, F-star Biotech
- Kapil Dhingra, MD, Managing Member, KAPital Consulting LLC
- Helen Tayton-Martin, PhD, MBA, Chief Business Officer, Adaptimmune
- Jill O'Donnell-Tormey, PhD, Chief Executive Officer & Director, Scientific Affairs, Cancer Research Institute
- Mark Simon, Managing Director, Torrey

1:45 – 3:00pm

**Networking Luncheon & Keynote:**

*The Biden Cancer Initiative: Helping to build the cancer research and care system you think we already have*

**Speaker:** Gregory C. Simon, President, Biden Cancer Initiative

3:00– 4:15pm

**Insights from Heme Malignancies: Making Breakthrough Conventional and Unconventional Therapies Accessible Beyond Niche Blood Cancer Patients**

**Moderator:** Michael C. Rice, MS, MBA, Principal, Cello Health BioConsulting, previously Defined Health

**Panelists:**

- Chris Bowden, MD, CMO, Agios Pharmaceuticals
- Lee Greenberger, VP and Chief Scientific Officer, The Leukemia & Lymphoma Society
- Dan Shoemaker, PhD, CSO, Fate Therapeutics
- Vatnak Vat-Ho, Vice President, Business Development, Affimed

4:15 – 5:30pm

**Oncology Innovation Powered by Investments and Competition from China**

**Moderator:** James T. Lee, PhD, Associate Principal, Oncology Lead, Cello Health BioConsulting, previously Defined Health

**Panelists:**

- Iris Luo, MS, MBA, Head of Business Development, North America, CStone Pharmaceuticals
- Ian Somaiya, CFO, TCR<sup>2</sup> Therapeutics
- Ian Woo, President & CFO, Everest Medicines
- Jack Wu, PhD, Head of Business Development (USA), Adlai Nortye

5:30pm

**Cancer Progress 2019 Conference Concludes**